Thu Nov 14 18:51:46 UTC 2024: ## Europe Approves Alzheimer’s Drug Leqembi After Reversing Earlier Decision
**Amsterdam, Netherlands** – The European Medicines Agency (EMA) has reversed its previous decision and granted conditional approval for the Alzheimer’s treatment Leqembi (lecanemab), marking a significant step forward in the fight against the debilitating disease.
The EMA’s initial rejection in July cited concerns about potential side effects, including brain bleeding, outweighing the benefits. However, after a reassessment, the agency has now recommended the drug for patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease who carry one or no copies of the ApoE4 gene, a known risk factor for the disease.
This conditional approval comes with stringent measures aimed at mitigating the risk of serious side effects, including the requirement for MRI scans before and during treatment. Leqembi will be available through a controlled access program, ensuring its use only in the recommended patient population.
The EMA’s decision now goes to the European Commission for final approval, paving the way for the drug’s availability across the continent. Pricing and reimbursement will be determined by individual member states.
Leqembi, developed by Biogen and Eisai, has garnered praise from Alzheimer’s researchers and charities for its innovative approach. It targets the early stages of the disease by clearing harmful proteins that accumulate in the brain. Clinical trials have demonstrated a 25% reduction in cognitive decline in patients with early-stage Alzheimer’s.
This approval marks a crucial development in the treatment of Alzheimer’s, providing hope for millions suffering from the disease and their families. It also reinforces the growing global recognition of Leqembi’s potential to significantly impact the future of Alzheimer’s care.
First Piper 